Prev:Next:

Prof. Wang has nearly 30 years of experiences in clinical works and in phase I~IV drug development and clinical trials of new drugs. Before returning to China, he studied and worked in the United States for more than ten years. During his stay in the United States, he served successively as a postdoc, scientist, senior scientist and chief scientist etc. He came back to China in 2014 and established an early phase clinical trial center for new drugs in full line with international standards (75 beds) which is the top one level quality standards of Beijing. He is also an expert on the development of new analytical methods for sensitive and accurate detection of the target drugs, which is especial beneficial for the clinical research of new drug. Prof. Wang has a lot of experience for antitumor phase 0/ phase I clinical trials of new drugs, and in macromolecular weight anti-tumor drugs, he is very familiar with clinical medication and new drug clinical trial design. Deputy director of the clinical research evaluation and quality professional committee of China medical quality management association

Deputy director of the clinical evaluation branch of education society of Chinese medicine

Vice President of children's safe medication branch of China children's news and information association

Assessment experts, audit expert and inspection expert in new drug of China CFDA

Assessment expert in biomedical medicine and new drug of Ministry of  Science and Technology/ Ministry of Human Resources and Social Security/ Ministry of Finance of the People’s Republic of  China

Assessment expert in biomedical medicine and new drug of Beijing Municipal Science & Technology Commission